At least 930 people have died in the Democratic Republic of Congo's Bundibugyo Ebola outbreak, the country's Ministry of Health announced Monday, July 20, 2026, with 37 new deaths recorded in a single 24-hour window spanning Friday into Saturday, one of the highest daily tolls since the crisis began. The deaths have occurred among 2,344 laboratory-confirmed cases, a figure that the WHO has warned represents only a fraction of actual transmission, given significant surveillance gaps across the conflict-affected region.
According to the European Centre for Disease Prevention and Control, 724 patients remain hospitalized in isolation as of the most recent data, while 466 have recovered. The outbreak was declared on May 15, 2026, and the WHO has characterized it as spreading faster than any previous Ebola outbreak on record.
Why This Matters
930 confirmed deaths is a sobering milestone in an outbreak that began just over two months ago. The 2014-2016 West Africa Ebola epidemic, which remains the largest in history by total cases and deaths, accumulated at a significantly slower early rate. The pace of this outbreak, which has gone from the first confirmed case in mid-May to nearly a thousand deaths by mid-July, reflects the compounding challenges of responding to Ebola in a region defined by armed conflict, disrupted health infrastructure, and healthcare workers walking off the job over unpaid wages.
The pathogen responsible, Bundibugyo ebolavirus, is also distinctly harder to fight than the Zaire strain that all prior response tools were designed around. There is no approved vaccine. There is no approved treatment. Ervebo, the Zaire-strain Ebola vaccine widely used in previous DRC outbreaks, does not reliably bind to Bundibugyo's surface proteins, and the WHO has formally recommended against using it outside controlled research settings for this outbreak. The same limitation applies to ZMapp and the monoclonal antibody cocktails developed for Zaire.
For the 930 confirmed dead, and for the thousands still at risk in eastern DRC, that gap is not a technical abstraction. It is the difference between a response capable of turning the epidemic curve and one that is still chasing it.
What We Know So Far
The outbreak is concentrated in five provinces of northeastern DRC: Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo. Ituri Province remains the epicenter, with 2,090 confirmed cases and 776 deaths from 27 of its 36 health zones, according to the NICD update and ECDC data. North Kivu has reported 230 cases and 139 deaths from 11 of its 34 health zones, signaling geographic spread beyond the original epicenter.
Uganda has separately confirmed 20 laboratory cases and 2 deaths, all linked to travel from DRC. France reported one confirmed imported case on June 24, 2026. Both exported cases occurred before these countries were under enhanced surveillance. Cross-border risk to Uganda, where the Lake Albert corridor creates significant population movement between the two countries, remains an active concern.
According to the Africa CDC, the overall case fatality rate is 39.7%, meaning nearly four of every ten confirmed patients are dying. The WHO has noted that this figure likely underestimates the true toll because an unknown number of cases are occurring and dying outside formal surveillance, particularly in conflict-affected areas where medical facilities are inaccessible or have been attacked.
Three first-ever clinical trials targeting the Bundibugyo strain specifically are currently enrolling patients, testing remdesivir, the monoclonal antibody MBP134, and the experimental vaccine candidate BD-Ebov, according to TechTimes. These are the only treatment tools now being evaluated under research conditions.
The response has also been crippled by direct attacks on health infrastructure. At least 12 attacks on medical facilities and healthcare teams have been recorded since mid-May. Dozens of healthcare workers have gone on strike to protest months of unpaid wages. At least 36 healthcare workers have died of Bundibugyo infection, representing one of the highest health worker toll rates in any Ebola outbreak.
Where the Risk Is Highest
Inside DRC, the highest risk is in Ituri Province and increasingly in North Kivu, where transmission has spread from the original outbreak zone. The conflict-affected areas, particularly where M23 and other armed groups operate near Goma and across the Ituri-North Kivu border, represent the most difficult surveillance and response environment.
For the United States, the direct risk remains very low. No domestic cases have occurred. Two U.S. citizens, both humanitarian workers in DRC, have tested positive and been medically evacuated to Germany, where both were treated. The CDC maintains a Level 2 travel notice for DRC (Practice Enhanced Precautions) and a Level 1 notice for Uganda.
Contact tracing is covering 85.8% of identified case contacts in Ituri, North Kivu, and Tshopo provinces, according to the ECDC, which reflects meaningful but incomplete surveillance given the scale of the outbreak and the number of unknown transmission chains.
What Doctors and Experts Say
The WHO's characterization of this as the fastest-growing Ebola outbreak on record is the most significant framing to understand the current moment. The 2018-2020 DRC outbreak, which lasted nearly two years and killed over 2,200 people, did not reach current case counts as quickly as this one has. The dynamics differ in part because this is a different virus species, in part because of the compounding crises of conflict and healthcare worker strikes, and in part because the absence of an approved vaccine removes the cornerstone tool that contained the prior outbreaks.
Clinical trials for remdesivir and MBP134 in Bundibugyo patients represent the global health community's most urgent current action. MBP134, developed by Mapp Biopharmaceutical, is a bispecific antibody cocktail that has shown cross-reactivity with Bundibugyo in laboratory studies. Whether it translates to clinical benefit in humans will be known only from the trial now underway.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Outbreak type: Active Ebola disease outbreak caused by Bundibugyo ebolavirus (BDBV); distinct from Zaire ebolavirus
- Confirmed cases (data through July 18, reported July 19-20, 2026): 2,344 laboratory-confirmed
- Deaths (July 20): 930 confirmed (data through July 18; ECDC and NICD)
- Case fatality rate: 39.7% (Africa CDC)
- Hospitalized: 724 in isolation
- Recovered: 466
- WHO classification: Public Health Emergency of International Concern (PHEIC), declared May 17, 2026
- Outbreak record: Fastest-growing Ebola outbreak on record per WHO
- Licensed vaccine: None for Bundibugyo virus
- Licensed treatment: None; clinical trials of remdesivir, MBP134, and BD-Ebov vaccine underway
- Healthcare worker deaths: At least 36
- U.S. domestic risk: Very low; no U.S.-soil cases
- What it does not show: Total true case count, which the WHO acknowledges is substantially undercounted due to surveillance gaps in conflict zones
- What readers should know: For most Americans, direct risk remains very low. The humanitarian crisis is severe. Travel to DRC requires CDC Level 2 precautions.
Who Faces the Greatest Risk?
The populations at highest risk are:
- Healthcare workers treating confirmed or suspected Bundibugyo patients in DRC, who face the most direct occupational exposure
- Residents of Ituri Province and North Kivu, where transmission is active and continuous
- Humanitarian workers, journalists, and aid organization staff operating in affected areas
- People in eastern DRC with recent attendance at funerals or close contact with Ebola patients, where traditional burial practices have historically driven transmission
- Travelers to DRC who do not follow enhanced precautions
For U.S.-based readers, the highest-risk category is Americans traveling to or working in DRC for humanitarian, medical, or journalistic purposes.
Symptoms and Warning Signs to Watch For
Anyone who has traveled to DRC or Uganda in the past 21 days and develops the following symptoms should isolate immediately and contact a health care provider before visiting any medical facility:
- Sudden high fever
- Severe headache and body aches
- Extreme fatigue
- Sore throat
- Vomiting and diarrhea
- Stomach pain
- Unexplained bleeding or bruising
- Nosebleeds or blood in stool or vomit in later stages
Call ahead before arriving at any clinic or emergency room. Identify yourself as a recent traveler to DRC or Uganda. Follow the instructions of health care staff for isolation and safe entry to the facility.
What You Can Do Now
- Americans planning travel to DRC should consult the CDC travel health notice for DRC (Level 2) before departure.
- Organizations deploying staff to DRC should provide updated WHO and CDC guidance and ensure all staff have clear symptom reporting protocols and evacuation plans.
- Returning travelers from DRC or Uganda who are symptom-free should self-monitor for 21 days per CDC guidance.
- Returning travelers who develop fever or other Ebola-consistent symptoms within 21 days of return should call their health care provider before visiting the office and disclose their travel history.
- Follow situation updates through the WHO disease outbreak page , the ECDC Bundibugyo tracker , and the CDC Ebola situation summary .
Cost and Access: What Patients Should Know
No FDA-approved Bundibugyo-specific treatment or vaccine is currently available. For any American who requires evaluation for potential Ebola exposure, care would be provided at one of the federally designated biocontainment units at academic medical centers, at no cost to the patient for initial evaluation. Pre-travel guidance for DRC-bound humanitarian workers is available through the CDC Travelers' Health website at no cost.
What Happens Next
Clinical trial results from the remdesivir, MBP134, and BD-Ebov studies will begin to accumulate in the coming weeks and months. The WHO Emergency Committee will reconvene periodically to assess the PHEIC designation. DRC health authorities and international partners are attempting to scale up contact tracing and isolation capacity. Healthcare worker strike negotiations are ongoing. MedicalDaily will continue reporting on death toll updates and any significant clinical trial findings.
The Bottom Line
930 people have now died in the DRC Bundibugyo Ebola outbreak, the fastest-growing Ebola epidemic on record. With 2,344 confirmed cases in five provinces, a 39.7% confirmed case fatality rate, no approved vaccine, no approved treatment, and clinical trials only now beginning to generate data, this outbreak remains an active and severe international public health crisis. For Americans, direct risk remains very low, but anyone involved in DRC travel or humanitarian work must follow Level 2 precautions and have clear contingency protocols in place.
